Navigation Links
New York Benefit to Celebrate Recent Medical Marijuana Successes
Date:5/13/2008

A Night of Music & Comedy to Help Push Campaign to Victory May 14, 2008 -

Highline Ballroom Spring Soiree to Benefit Effort to Protect Seriously Ill New York Patients

Who Use Medical Marijuana

NEW YORK, May 13 /PRNewswire/ -- The Marijuana Policy Project (MPP.org) will host a spring soiree, a night of comedy and music to benefit MPP's efforts to protect seriously ill New Yorkers from arrest and jail if they use medical marijuana with their doctor's recommendation. Patient advocate Joel Peacock will be honored and Sony/BMG artist Nicole Atkins & The Sea and others will perform.

MPP is leading the fight to gain medical marijuana access for seriously ill New Yorkers who have the approval of their physicians. All funds raised will be used to pass a bill to make New York the 13th medical marijuana state in the country.

The Host Committee for the event and those attending include: Joshua Baer, John Perry Barlow, Paul Bennett, Lewis Black, State Senator Joseph Bruno's Director of Public Affairs in New York City Lisa Black, Richard Brookhiser, Tucker Carlson, Jason Flom, Savion Glover, Leslie Lansman, David C. Leven, Peter Lewis, Kurt Loder, Fred Newton, Medeski Martin and Wood, Michelle Phillips, ABC's John Stossel, Ben Taylor, Montel Williams and Robert W. Wilson.

Last year -- for the first time ever -- the New York Assembly passed MPP's medical marijuana bill by a 95-52 vote, sending the bill over to the Senate. This was the result of a four-year lobbying effort that we commenced in 2003.

MPP.org's lobbyist in Albany built an impressive coalition of institutional support, including the state physicians association, state nurses association, state public health association, and the city councils of Albany, Buffalo, and New York.

New York Senate Majority Leader Joseph Bruno is supportive of allowing medical marijuana, but has not brought the issue to a vote.

With
'/>"/>

SOURCE MPP.org
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Interventional Cardiologists Nico Pijls, Bernard De Bruyne to Discuss Benefits of Measuring Coronary Pressure in Improving Multivessel PCI at ESC Congress 2007
2. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
3. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
4. Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund
5. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
6. Care to Care Begins Providing Radiology Benefit Management Services to Touchstone Health
7. Cord Blood America Says Pennsylvania Joins New York and California in Establishing Educational Programs on the Benefits of Umbilical Cord Blood Storage
8. Improved governance needed to realize nanotechs benefits
9. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
10. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
11. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... RainDance Technologies, Inc., a,provider of innovative microdroplet-based ... the relocation of the company from,Guilford, Connecticut, to ... facility and start up commercial and manufacturing operations,effective ... our first life sciences application scheduled for,the fourth ...
... Epeius Biotechnologies,announced today the results of an on-going ... et al., ASCO meeting, 2008).,Continuing on with the planned ... of Rexin-G in a Phase I safety study (Molecular,Therapy, ... Rexin-G given i.v. two to three times a week ...
... Replikins Ltd. has found that very high,concentrations ... the,trypanosomes that are the infectious agents in malaria. ... the highest replikin concentrations observed to,date in any ... that these,concentrations cycle over several years., Replikins ...
Cached Biology Technology:RainDance Announces Company Relocation and Manufacturing Startup 2ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer 2Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes 2
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... first time, large-scale information on the biochemical makeup ... publicly. These molecules are used in research to ... disease. Making these data accessible to researchers worldwide ... patients. NIH,s National Center for Advancing ...
... As coastal communities continue to rebuild in the ... meeting of the American Geophysical Union offer some encouraging ... barrier system that controls erosion on Long Island. Long-term ... sea-level rise, pollutants churned up by the storm within ...
... , Dec. 10, 2013  KaloBios Pharmaceuticals, Inc. ... results of an ongoing multi-center Phase 1 study ... company is developing as a treatment for hematologic ... were unfit for chemotherapy have been enrolled in ...
Cached Biology News:Gene-silencing data now publicly available to help scientists better understand disease 2Gene-silencing data now publicly available to help scientists better understand disease 3Post-Sandy, Long Island barrier systems appear surprisingly sound 2Post-Sandy, Long Island barrier systems appear surprisingly sound 3KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 2KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 3KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 4KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 5
... Acetate: CoA ligase (AMP forming), Acetate ... on protein content. Physical form: ... sucrose and reduced glutathione Preparation ... mol of S-acetyl coenzyme A from acetate, ...
...
... 15(S)-15-methyl PGF2α is a ... It is a potent uterine ... be administered intramuscularly to induce ... reduces serum progesterone concentrations when ...
... Biochem/physiol Actions: Glutathione-S-transferases (GSTs) are a group ... many xenobiotics in mammals. The enzymes ... thiol group of the glutathione to electrophilic ... mutagenic, carcinogenic, and toxic effects of the ...
Biology Products: